NCT06821100View on ClinicalTrials.gov

Thymalfasin (Thymosin Alpha 1; Ta1) as an Enhancer of Vaccine Response Among Older Adults Receiving Booster Doses of COVID-19 Vaccine

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 2, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions

Vaccine ResponseCOVID-19 VaccineImmune Response to Covid 19 Vaccination

Interventions

DRUG

Thymalfasin (Thymosin alpha 1, Ta1)

Ta1 is a naturally occurring peptide that has been evaluated for its immunomodulatory activities and related therapeutic potential in several conditions and diseases. Ta1 has been shown to provide increased response to vaccines.

Trial Locations (1)

77030

RECRUITING

Houston Methodist Hospital, Houston

All Listed Sponsors

lead

The Methodist Hospital Research Institute

OTHER